TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02442752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole capsules
Study: NCT06389604

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat acclimation
Description: Daily repeated heat exposure to assess the effects of combined passive and active heat acclimation
Study: NCT05238727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.8 ml mepivacaine hydrochloride
Description: 1.8 ml mepivacaine IANB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.6 ml mepivacaine hydrochloride
Description: 3.6 ml mepivacaine IANB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.8 ml mepivacaine hydrochloride IANB plus 1.8 ml articaine hydrochloride BI
Description: 1.8 ml mepivacaine IANB plus 1.8 ml articaine BI
Study: NCT02442752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole capsules
Study: NCT06305637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole Shampoo, 2%
Description: The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole Shampoo, 2% (Reference Standard)
Description: The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.
Study: NCT05148546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab
Description: Patients will receive 2 cycles of nivolumab 360mg (arm A and C) or 3mg/kg (arm B) every 3 weeks followed by a nephrectomy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab
Description: Patients will receive 2 cycles of nivolumab 360mg (arm A and C) or 3mg/kg (arm B) every 3 weeks followed by a nephrectomy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab
Description: Patients will receive 2 cycles of nivolumab 360mg (arm A and C) or 3mg/kg (arm B) every 3 weeks followed by a nephrectomy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant ipilimumab
Description: Patients will receive 2 cycles of ipilimumab 1mg/kg every 3 weeks followed by a nephrectomy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant relatlimab
Description: Patients will receive 2 cycles of relatlimab 360mg every 3 weeks followed by a nephrectomy.
Study: NCT05115851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anodal tDCS cerebellar stimulation group
Description: three-session ctDCS (2 mA, 20 min). The active (anode) and the returning (cathode) electrodes will be placed bilaterally over the cerebellum (1 -2 cm below inion of occipital bone) and the right buccinator muscle, respectively xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anodal tDCS cerebral (M1) stimulation group
Description: three-session a-tDCS (2 mA, 20 min), the anode will be positioned over the lesioned M1 (C3, International 10-20 system) and the cathode would be located over the supraorbital area. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Group
Description: three-session a-tDCS (2 mA, 20 min), Sham tDCS followed a similar protocol as Anodal tDCS cerebral (M1) stimulation and arrangement but stimulation for 30 s, after which the current was ramped-down and turned off for the rest of the treatment. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
Study: NCT05272111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBM fasciatherapy+ conventional physical therapy
Description: DBM fasciatherapy (3 sessions per day). It soft, deep and non-manipulative form of treatment that involves the application of gentle pressure while stretching the body's connective tissue. A specialized form of touch, somatic sense, and specific body movement protocols are the three steps involved in the fasciatherapy. + hot pack (10 min) + neck isometrics (neck flexion, extension, side bending) + neck stretches (neck flexors, extensors, side benders and rotation). A total of 45 min session three times a week on alternate days for three weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fascial manipulation+ conventional physical therapy
Description: Fascial manipulation (3 sessions per day). This technique involves the identification of specific, localized areas of the fascia with limited movements. Once it is identified, then a specific point on the fascia is targeted and through the appropriate manipulation of this precise part of the fascia, movement can be restored. + hot pack (10 min) + neck isometrics (neck flexion, extension, side bending) + neck stretches (neck flexors, extensors, side benders and rotation). A total of 45 min session three times a week on alternate days for three weeks
Study: NCT06104020

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative fluid management stratigies.
Description: Regimens of different intraoperative fluid management The restrictive fluid group (RG) aims to achieve a net zero fluid balance and involves a 2 mL/kg bolus at anesthesia induction, followed by an intraoperative crystalloid infusion at a rate of 4 mL/kg/hr.~The other group of patients, the liberal group (LG), will receive a 10 ml/kg bolus at anesthesia induction,followed by an intraoperative crystalloid infusion at a rate of 8 ml/kg/hr.
Study: NCT05014594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin (10Mg Tab) along with standard medical therapy
Description: Oral Dapaglifozin (10 mg/day) along with standard medical therapy will be given to Group A while a placebo of dapaglifozin along with standard medical therapy will be used in Group B

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of dapaglifozin along with standard medical therapy
Description: Standard medical therapy will include dietary restriction of sodium, treatment with diuretics, repeated LVP as needed and other supportive care. Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
Study: NCT06388343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of Children's Listening and Processing Skills
Description: The Evaluation of Children's Listening \& Processing Skills (ECLiPS; (Barry \& Moore, 2021; Barry et al., 2015; Petley et al., 2021) is a caregiver-report outcome measure to profile auditory and cognitive real-world abilities important for successful listening and (auditory) processing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of Children's Listening and Processing Skills
Description: The Evaluation of Children's Listening \& Processing Skills (ECLiPS; (Barry \& Moore, 2021; Barry et al., 2015; Petley et al., 2021) is a caregiver-report outcome measure to profile auditory and cognitive real-world abilities important for successful listening and (auditory) processing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary behavioral assessment
Description: By collecting behavioral measures, the investigators wish to understand the functional implications of the presented problems. Children will complete various well-chosen tasks using a tablet, in the presence of a trained clinician. Tablets are used as they are ubiquitous, cost-effective, and have excellent quality audio output. The investigators will apply the concept of differential testing (Dillon \& Cameron, 2021; Lagacé et al., 2010) to narrow down the range of deficits that lead to deficient scores. The investigators distinguish four (partly overlapping) categories of behavioral measures: 1) auditory processing, 2) (nonsense) speech sound processing in quiet and in noise, excluding semantics, 3) meaningful speech in quiet and in noise, language processing, and 4) neurocognitive (including attention, memory, processing speed) processing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary behavioral assessment
Description: By collecting behavioral measures, the investigators wish to understand the functional implications of the presented problems. Children will complete various well-chosen tasks using a tablet, in the presence of a trained clinician. Tablets are used as they are ubiquitous, cost-effective, and have excellent quality audio output. The investigators will apply the concept of differential testing (Dillon \& Cameron, 2021; Lagacé et al., 2010) to narrow down the range of deficits that lead to deficient scores. The investigators distinguish four (partly overlapping) categories of behavioral measures: 1) auditory processing, 2) (nonsense) speech sound processing in quiet and in noise, excluding semantics, 3) meaningful speech in quiet and in noise, language processing, and 4) neurocognitive (including attention, memory, processing speed) processing.
Study: NCT06308939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: 1.4mg/m\^2 day1、8，repeated every 3 week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 500mg once every three weeks.
Study: NCT06316986

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pH indication with NGPOD
Description: The NGPOD sensor is inserted into the naso- or oro-gastric tube, then reconnected to the NGPOD handheld device, and the pH measurement is taken within 15 seconds.~When the 15 seconds have elapsed, the pH button is pressed. If the green LED lights up and the pH indicates a value \< 5.5, the sensor tip is in a pH environment associated with the stomach.~If the red LED lights up, the sensor tip is in a pH environment NOT associated with the stomach.
Study: NCT06183801

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics 1
Description: Subjects take probiotics capsule(Lactobacillus fermentum,TSF331) three times a day before meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics 2
Description: Subjects take probiotics capsule(Lactobacillus reuteri,TSR332) three times a day before meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics 3
Description: Subjects take probiotics capsule(Lactobacillus plantarum,TSP05) three times a day before meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics 4
Description: Subjects take probiotics capsule(Lactobacillus fermentum,TSF331+Lactobacillus reuteri,TSR332+Lactobacillus plantarum,TSP05) three times a day before meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics 5
Description: Subjects take probiotics capsule(Lactobacillus fermentum,TSF331+Lactobacillus reuteri,TSR332+Lactobacillus plantarum,TSP05+Postbiotics PE0401) three times a day before meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1
Description: Subjects take capsule three times a day before meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics 6
Description: After 1 month wash out, subjects take probiotics capsule(Bifidobacterium animalis subsp. lactis,CP-9) three times a day before meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics 7
Description: After 1 month wash out, subjects take probiotics capsule(Lactobacillus rhamnosus, bv-77+Bifidobacterium animalis subsp. lactis,CP-9) three times a day before meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2
Description: After 1 month wash out, subjects take capsule three times a day before meal.
Study: NCT05605119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUR105
Description: Once daily
Study: NCT04634604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: For infants randomized to bevacizumab, the Intravitreous bevacizumab 0.063 mg injection will be given no later than 2 days after the diagnosis of type 1 ROP. The ophthalmologist may choose to give the intravitreous injection in the operating room or at the bedside, with or without anesthesia, after consultation with the attending neonatologist. A binocular indirect ophthalmoscope with an appropriate condensing lens should be available, and the pupils should be dilated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: For infants randomized to laser treatment, it will be given in conjunction with a binocular indirect ophthalmoscope and an appropriate condensing lens, by a study-certified ophthalmologist experienced in the use of this equipment. The treating investigator will be certified as having sufficient experience with laser for ROP, and adequacy of laser treatment will be confirmed by expert review of photographs. Special laser precautions, as mandated by OSHA and facility standards, will be followed.
Study: NCT06529588

Intervention type: RADIATION
Intervention: Radiation
Description: HNCs patients who received radiotherapy was exposure (5700-7000 Gys) for fractions number (32-35) after 6 months
Study: NCT06226896

Intervention type: DRUG
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin 10mg daily plus RAS inhibitor
Study: NCT05225818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLAN - Home
Description: home-based intervention program for dementia evaluation, education, and care planning
Study: NCT06152536

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vegetarian Meal
Description: meal with vegetarian protein and meal with animal protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegetarian Meal
Description: meal with vegetarian protein and meal with animal protein
Study: NCT06486740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mesofiller aox
Description: The investigated product M-AOX-2021 was applied by intradermal or subcutaneous injection by the investigator during Session 1 for all subjects and Session 2 for the subjects, for whom a touch-up was considered beneficial. The both sessions was conducted within 14 days interval.
Study: NCT05712291

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total knee arthroplasty using the active robotic surgical system
Description: Total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan

Intervention type: DEVICE
Group type: OTHER
Intervention: TSolution One TCAT, and system for planning TPlan
Description: the active robotic surgical system TSolution One TCAT, and system for planning TPlan

Intervention type: PROCEDURE
Group type: OTHER
Intervention: total knee arthroplasty using the standard manual technic
Description: total knee arthroplasty using the standard manual technic
Study: NCT06364189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Individualized play lists of music with the beats accentuated will be developed at a range of cadences. The music intervention is such that during strength training participants will be asked to sync their concentric and eccentric muscle contractions in time with the tempo of playlists. For aerobic exercise (AE), the tempo of playlists will be adjusted to match individual walking cadence for participants to be trained to walk in sync with the beats of the playlists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The ST incorporates single-leg exercises for balance training and training with resistance bands and body weight.~For aerobic exercise (AE), participants will be instructed to walk at moderate intensity with duration increasing up to an ultimate goal of 150 min/week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The ST incorporates single-leg exercises for balance training and training with resistance bands and body weight.~For aerobic exercise (AE), participants will be instructed to walk at moderate intensity with duration increasing up to an ultimate goal of 150 min/week.
Study: NCT05094323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided deep serratus anterior plane block with isobaric bupivacaine
Description: Patients will receive ultrasound-guided deep serratus anterior plane block with isobaric bupivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local wound infiltration with isobaric bupivacaine
Description: Patients will receive local wound infiltration with isobaric bupivacaine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound-guided thoracic paravertebral block with isobaric bupivacaine
Description: Patients will receive ultrasound-guided thoracic paravertebral block with isobaric bupivacaine.
Study: NCT05639946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brivaracetam
Description: Drug dosage will be individually titrated for each participant with a goal of 100mg BID according to the following dose escalation protocol that we use clinically: 50mg BID for 2 weeks, followed by 50mg TID for 2 weeks, followed by 100mg BID for 48 days as tolerated. Participants will be allowed to reduce the dose of brivaracetam if they experience unacceptable side effects defined as increased somnolence according to routine clinical practice with other drugs in this class used for pain.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo drug
Study: NCT06554288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trihexyphenidyl
Description: 6-week dose escalation up to 0.25mg/kg TID, followed by a 9-week maintenance period at this dose
Study: NCT06386510

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strength training
Description: The strength training program will last 4 weeks (3 X/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM for the wrist extensors and the elbow and shoulder flexors. The grip muscles of the affected hand will also be trained with a JAMAR® dynamometer. Depending on each participant's intensity training group, training will start at 35%, 50% or 70% of 1RM and will be increased by 5% each week to reach, by week 4, 50%, 65% and 85%, for the low, moderate, and high-intensity group, respectively.
Study: NCT05108233

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study: NCT06634927

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozempic®
Description: Participants will be given Ozempic ® injection 0.25mg abdominal subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDG1901
Description: Participants will be given HDG1901 injection 0.25mg abdominal subcutaneous injection.
Study: NCT06636552

Intervention type: DRUG
Group type: OTHER
Intervention: Daratumumab (Subcutaneously)
Description: D-PAD (21-Day Cycles 1, 3 and 5):~1,800 mg (QW) SC on days 1, 8, and 15 (for Cycles 1 and 3) 1,800 mg (Q3W) SC on day 1 (for Cycle 5)~D-CVD (21-Day Cycles 2, 4, 6, 7 and 8):~1,800 mg (QW) SC on days 1, 8, and 15 (for Cycle 2) 1,800 mg (Q3W) SC on day 1 (for Cycles 4, 6, 7 and 8)~Daratumumab monotherapy (28-Day Cycles 9 to 32):~1,800 mg (Q4W) SC on day 1
Study: NCT06635395

Intervention type: OTHER
Intervention: Scale validity and reliability
Description: The aim of this study is to adapt the Baltimore Orthopedic Subscapularis Score (BOSS) to Turkish society in patients with rotator cuff injury and to make its validity and reliability in Turkish. It has 5 questions. The patients will be sought to answer questionnaires during regular rehabilitation sessions.
Study: NCT05802810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]JT001
Description: Subjects will receive approximately 300 mg/100 µCi of \[14C\]JT001 orally.
Study: NCT05787418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH-120 Nasal Spray
Description: HH-120 nasal spray 8 times per day for 7 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 8 times per day for 7 consecutive days
Study: NCT06582615

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo dried blood spot collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo dried blood spot collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Receive MIND counseling sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Follow a personalized diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: Receive general health recommendations counseling sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear a Fitbit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Wear a Fitbit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06401148

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac rehab intervention group
Description: Participants will complete an 8-week cardiac rehabilitation programme supported by the onsite CR service.
Study: NCT06543979

Intervention type: DRUG
Group type: OTHER
Intervention: lubiprostone , single arm
Description: laxative

Intervention type: PROCEDURE
Group type: OTHER
Intervention: biofeed back sessions
Description: Biofeedback for participants with dyssynergic defecation and participants with reduced rectal sensations

Intervention type: PROCEDURE
Group type: OTHER
Intervention: botox injection
Description: Botulinum toxin injection for participants suffering from elevated anal canal pressure
Study: NCT06088654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPH6501
Description: phase 1 (dose finding) and phase 2 (dose expansion)
Study: NCT06230757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin 25mg
Description: 25mg psilocybin capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (active placebo)
Description: 1mg psilocybin capsule